We have shown that the use of accelerated dose (AD) induction of infliximab (IFX) reduces short-term colectomy rates in ASUC, but long-term data are limited. The aim of this study was to evaluate medium to long-term outcomes in patients receiving IFX induction for ASUC, comparing AD induction and standard dose (SD) induction. Methods: Retrospective study of all consecutive patients admitted with corticosteroid-refractory ASUC in 4 tertiary referral centres within the INITIative IBD research network (www.initiativeibd. ie). Patients received rescue IFX either as Standard dose (SD) induction (Weeks 0, 2, 6) or AD induction (<42 days) from January 2010 to September 2017. AD induction has been in routine clinical use since 2014. SD patients were sub-divided based on the time period of IFX rescue: historical SD group (SD1) [2010][2011][2012][2013] and current SD group (SD2) [2014][2015][2016][2017]. Demographics were collected at time of induction. Primary end-point was time to colectomy, with secondary end-point of time to IFX discontinuation in those completing induction. Results: A total of 145 patients received rescue IFX for steroid refractory ASUC (AD = 58, SD1 = 32, SD2 = 55). Disease severity at induction was comparable between the AD group and SD1, but SD2 had less severe disease. Median CRP was 39, 44, and 20 mg/l for groups AD, SD1 and SD2, respectively (p = 0.026, Kruskal-Wallis). Median CRP: albumin ratio was 1.4, 1.8, and 0.6 for groups AD, SD1 and SD2, respectively (p = 0.016). Median follow-up for each group was 1.9, 4.9, and 1.5 years. Kaplan-Meier survival analysis ( Figure 1 ) revealed a significant difference in time to colectomy across the groups, with higher rates of colectomy in SD1 original group (log-rank p = 0.0013). No significant difference was observed between AD and SD2 (log-rank p = 0.32).123 (84%) completed IFX induction, receiving maintenance therapy. Time to IFX discontinuation was significantly shorter in SD1 group, and comparable between AD and SD2 current (log-rank p = 0.009).
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We have shown that the use of accelerated dose (AD) induction of infliximab (IFX) reduces short-term colectomy rates in ASUC, but long-term data are limited. The aim of this study was to evaluate medium to long-term outcomes in patients receiving IFX induction for ASUC, comparing AD induction and standard dose (SD) induction. Methods: Retrospective study of all consecutive patients admitted with corticosteroid-refractory ASUC in 4 tertiary referral centres within the INITIative IBD research network (www.initiativeibd. ie). Patients received rescue IFX either as Standard dose (SD) induction (Weeks 0, 2, 6) or AD induction (<42 days) from January 2010 to September 2017. AD induction has been in routine clinical use since 2014. SD patients were sub-divided based on the time period of IFX rescue: historical SD group (SD1) [2010] [2011] [2012] [2013] and current SD group (SD2) [2014] [2015] [2016] [2017] . Demographics were collected at time of induction. Primary end-point was time to colectomy, with secondary end-point of time to IFX discontinuation in those completing induction. Results: A total of 145 patients received rescue IFX for steroid refractory ASUC (AD = 58, SD1 = 32, SD2 = 55). Disease severity at induction was comparable between the AD group and SD1, but SD2 had less severe disease. Median CRP was 39, 44, and 20 mg/l for groups AD, SD1 and SD2, respectively (p = 0.026, Kruskal-Wallis). Median CRP: albumin ratio was 1.4, 1.8, and 0.6 for groups AD, SD1 and SD2, respectively (p = 0.016). Median follow-up for each group was 1.9, 4.9, and 1.5 years. Kaplan-Meier survival analysis ( Figure 1 ) revealed a significant difference in time to colectomy across the groups, with higher rates of colectomy in SD1 original group (log-rank p = 0.0013). No significant difference was observed between AD and SD2 (log-rank p = 0.32).123 (84%) completed IFX induction, receiving maintenance therapy. Time to IFX discontinuation was significantly shorter in SD1 group, and comparable between AD and SD2 current (log-rank p = 0.009). Conclusions: Time to colectomy is significantly prolonged with use of accelerated dose IFX in selected ASUC patients with more severe disease. The historic use of standard IFX induction for all ASUC patients is associated with inferior long-term outcomes. These data further support the use of AD IFX induction in selected patients with corticosteroid-refractory ASUC.
